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Mantle cell lymphoma (MCL) is a rare hematopoietic malignancy characterized by frequent 
relapses and poor survival, partly due to minimal residual disease, whereby a subset of 
malignant cells, harbored in protective niches, survive treatment. In vitro and ex vivo 
experiments have shown that MCL cells can be rescued from apoptosis through interactions 
with non-malignant cells such as stromal cells. The present thesis investigates the effect that 
extrinsic microenvironmental interactions may exert on MCL cells and discuss the 
presumptive role of these as well as intrinsic mechanisms in the development and progression 
of lymphomas. 
MCL cells commonly grow in suspension but when co-cultured with stromal cells a fraction 
of the MCL cells strongly attached to the stromal cell monolayer. Analysis of transcript levels 
by next generation sequencing and species-specific read separation we identified sets of 
genes with altered transcript levels between the adherent MCL cells and those that remained 
in suspension. These genes could broadly be divided into four functional themes of which 
three exhibited increased transcript levels in the adherent fraction: B-cell signaling, anti-
apoptosis and cell adhesion/migration, and one, early mitosis for which the associated genes 
exhibited lower transcript levels in the adherent MCL fraction. Additionally, we observed a 
significant overlap between the changed genes in the present co-culture model system and 
genes that change at the mRNA level between lymph node and cells in circulation in material 
from MCL and chronic lymphocytic leukemia patients. Suggesting that the model system 
faithfully represent aspects of microenvironment-promoted changes to the lymphoma cells 
also observed in vivo. As different MCL cell lines were subject to similar co-culture 
conditions we observed differences in engagement of and dependency on cell surface 
molecules, including the B cell receptor, for adhesion to stromal cells. Different responses to 
microenvironmental interactions for different MCL cells may therefore affect how different 
patients or different subsets of MCL cells within a patient will respond to different therapy 
regimens. 
The transcription factor SOX11 is a key diagnostic marker in MCL. Commonly not expressed 
in hematological malignancies it is expressed in 90% of MCL cases and most importantly 
identifies cyclin D1 negative MCL. Its role in MCL development and progression is however 
debated. Here we show that in the context of the non-malignant pre-B-cell-like cell line Ba/F3 
SOX11 does not exhibit oncogenic properties.  
MYC is a transcription factor that is capable of regulating the expression of a vast and diverse 
set of genes and has a role in lymphoma development, progression and disease prognosis for 
many lymphoma types, including MCL. Here we show that progressively increasing MYC 
levels in B-cells lead to the gradual change in expression in a large set of genes and 
importantly the gradual increase of two lymphoma-associated MYC mutants significantly 
altered transcript levels differently from wild type MYC. Gene set enrichment analysis 
identified functions previously associated with regulation by MYC such as ribosome 
biogenesis and purine metabolism, while other, novel functions such as those related to B-
cell identity and chemotaxis were observed. The MYC regulated genes overlapped with 
previous gene signatures observed in the Eµ-Myc mouse model and also with recently 
identified direct MYC targets, collectively indicating the utility of the present model system 
with inducible MYC for the identification of MYC dependent functions in lymphomagenesis. 
Two studied lymphoma-associated MYC mutants differentially affect largely distinct subsets 
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1 INTRODUCTION 
1.1 B-CELL LYMPHOMAS 
Normal B-cell differentiation and maturation depend on intrinsic and extrinsic signaling 
mechanisms where survival, proliferation, genomic rearrangements and mutations are 
supported at one or several instances during development. The process of B-cell development 
is inherently prone to malignant transformation given that the processes involved in antibody 
diversification may lead to unwanted chromosomal aberrations and oncogenic mutations. B-
cell lymphomas are a heterogeneous group of malignancies, with different manifestations 
and clinical outcomes that acquire the first oncogenic event at some stage during B-cell 
development.1,2 This first event may give survival advantages during further differentiation 
steps. The ultimate transformative event occurs later and can occur at different stages of the 
B-cell differentiation process. Consequently, the transformed B-cells will have a 
phenotypical resemblance to a normal B-cell counterpart at a particular developmental stage 
which may be reflected in terms of V(D)J rearrangements, IGHV mutation status as well as 
in distinct gene expression profiles and cell morphology. For example, the disease-defining 
oncogenic event in mantle cell lymphoma (MCL) occurs during the VDJ rearrangement of 
the immunoglobulin genes at the pre-B-cell stage, a translocational event juxtaposes cyclin 
D1—which is normally required for the G1/S cell cycle transition—to the immunoglobulin 
heavy chain promoter, leading to deregulated expression and an aberrant cell cycle. This 
genetic event is however not sufficient to drive malignant transformation, as circulating B-
cells carrying the MCL-associated translocation above have been observed in healthy 
individuals,3 and secondary oncogenic events are required to promote malignant 
transformation. 
The normal cellular counterpart for the majority of MCL cases and some cases of chronic 
lymphocytic leukemia (CLL) is the naïve, pre-germinal center B-cell and these cases are 
typically associated with an aggressive disease phenotype and a poor clinical outcome. For 
some MCL and CLL cases however the cell of origin is an antigen-experienced cell that has 
acquired somatic mutations when passing through the germinal center. Germinal center B-
cell-like diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Burkitt’s 
lymphoma (BL) have their normal counterpart in the germinal center B-cell while activated 
B-cell-like DLBCL and mucosa associated lymphoid tissue lymphoma (MALT) resemble 
post-germinal center B-cells. The most common B-cell lymphomas are FL and DLBCL, 
comprising between 50-60% of B-cell lymphoma cases worldwide. In some B cell 
lymphomas such as FL, BL and MCL, key translocational events—where the oncogenes 
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BCL2, MYC and CCND1, respectively, are erroneously joined to the heavy chain locus on 
chromosome 14, leading to their constant activation—are present in the vast majority of 
cases. As these genomic rearrangements alone are not sufficient to induce malignant 
transformation, secondary genomic aberrations altering key pathways are necessary for 
cancer progression. While key translocational events related to the immunoglobulin heavy 
chain locus are considered hallmarks of these three B-cell lymphomas, most cases retain one 
allele of the immunoglobulin heavy chain locus and have the ability to express a functional 
B-cell receptor and can take advantage of its downstream signaling for increased survival 
and proliferative responses. 
1.2 MANTLE CELL LYMPHOMA 
1.2.1 Etiology and epidemiology of MCL 
Mantle cell lymphoma (MCL) is an aggressive and in most cases incurable B-cell neoplasm 
that was recognized as a distinct non-Hodgkin’s lymphoma (NHL) subtype in the early 1990s. 
MCL comprises about 7% of the NHL cases and it is characterized by a generally high relapse 
rate and mortality.1 As in most NHL subtypes there is a strong male predominance among 
MCL cases (2.3–2.5 male to female ratio) and the median age at diagnosis is 67 years and 70 
years for men and women respectivly.4,5 Patients commonly present with advanced stage 
disease at diagnosis and more than 90% of the cases have extra-nodal manifestations with 
bone marrow (> 60% of cases) and gastrointestinal involvement.6,7 The most recent 
classification of MCL makes a distinction between two main groups, the first one being 
classic MCL, which is typically IGHV unmutated, SOX11+, genomically unstable with lymph 
node or extra-nodal involvement, and the second group being leukemic, non-nodal MCL 
which is typically negative for SOX11, genomically stable, carrying mutated IGHV.2 Four 
main cytological variants of MCL are recognized: small cell, classic, pleomorphic and 
blastoid, ordered according to progressively worse disease outcome. The small cell type has 
often been found in MCL patients with tumors that follow an indolent clinical course. 
While the median overall survival time has doubled over the past years—from 3–4 years to 
5–7 years—the prognosis for MCL patients is usually poor and fewer than 15% of patients 
are long-term survivors.8–10 There is however a small subgroup of patients (10–15%) with 
indolent disease, that may benefit from being left untreated under close supervision as the 
postponed therapy of these cases will not affect the clinical outcome.11,12 A subset of the 
indolent cases are characterized by a non-nodal, leukemic disease presentation but also 
certain cases with nodal involvement have a slow disease course and a long survival without 
treatment.13 There is a high risk of over-treatment due to the difficulty of diagnosing the 
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indolent disease type. These indolent cases have a higher number of somatic mutations in the 
IGHV locus and while the majority of cases are positive for the MCL hallmark translocation 
t(11;14)(q13;q32) they carry few other genetic aberrations.14 When gene expression profiles 
were compared between indolent forms of MCL, conventional MCL and several other B-cell 
neoplasms the indolent MCLs showed a greater similarity to conventional MCL than to any 
other cell type in the study.15 Thus this study showed that the indolent cases were indeed true 
MCL and not a subtype of other less aggressive B cell lymphomas such as CLL. Indolent 
MCL may progress into a more aggressive form at a later stage, often through the loss of a 
functional TP53 pathway. 
In MCL, the Ki67 proliferative index is considered the most reliable prognostic factor for 
predicting long-term patient outcome.16,17 A gene expression profiling study found a strong 
correlation between high expression of a proliferative gene signature consisting of 20 genes 
and poor survival.18 Patients with the highest expression of proliferation index genes had a 
median survival of 0.8 years while those in the study with lowest expression had a median 
survival of 6.7 years.18 In addition, deletions of genomic regions containing CDKN2A and 
TP53 have been correlated with poor survival.19 
1.2.2 MCL Phenotype 
MCL was thought to derive from naïve, pre-germinal B-cells. Recent findings however 
suggest that a fraction of MCL cases (15–40%) show evidence of antigen experience 
manifested in the observed somatic mutations within the immunoglobulin genes, this patient 
subset has been associated with an indolent course and a more favorable clinical outcome.20–
22 A similar division has been observed in CLL where Ig-unmutated cases have been 
correlated with an inferior prognosis. Additionally, while stereotypically different from those 
observed in CLL, a bias in regards to the BCR repertoire has been reported in MCL, hinting 
of a role for antigen-driven clonal selection in subsets of MCL. While indolent MCL often 
have a higher number of somatic mutations in IGHV, a prognostic role for the IGHV mutation 
status in MCL is yet to be described. The immunophenotype of MCL is reminiscent of a 
mature naïve B-cell (CD19+, CD20+, CD45+, CD24+) with a medium to strong IgM 
expression along with CD5+, CD10- and CD23- (In contrast, CLL has weak expression of 
CD20 and surface Ig and it is positive for both CD5 and CD23).12 
1.2.3 Cyclin D1 
As mentioned above, the defining feature of MCL is the t(11;14)(q13;q32) translocation 
which brings the cyclin D1 gene (CCND1) under the control of the immunoglobulin heavy 
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chain enhancer, leading to constitutive expression.23,24 Binding of cyclin D1 to CDK4 or 
CDK6—which are both commonly overexpressed in MCL—activates E2F through 
phosphorylation of its inhibitor, the tumor suppressor RB1, which leads to a deregulation of 
the cell cycle promoting cells to undergo the G1/S transition. The cyclin D1/CDK4 complex 
can in addition enable cyclin E/CDK2 activation by binding its repressor p27Kip1 (is encoded 
by the CDKN1B gene), which in turn promotes further phosphorylation of RB1 and promotes 
entry into the S phase. Furthermore, additional mechanisms resulting in CCND1 
overexpression have been observed in MCL. CCND1 contains 5 exons that can be alternately 
spliced into two isoforms; cyclin D1a and D1b. While the latter is not involved in MCL 
pathogenesis, cyclin D1a is detected in virtually all CCND1 overexpressing MCL cases and 
harbors a destabilizing 3’ UTR that, when truncated by chromosomal rearrangements or 
mutations, stabilizes the transcript leading to increased CCND1 levels. Truncated CCND1 
transcripts have been correlated with poor survival.25,26 In rare cases CCND1 levels can be 
further elevated by amplification events affecting the t(11;14)(q13;q32) region.27 
Interestingly, apart from the involvement of CCND1 in cell cycle progression, it has also 
been shown to bind RAD51 to promote DNA repair and homologous DNA recombination28 
and to impair the function of the proapoptotic protein BAX through direct interaction.29 
The t(11;14)(q13;q32) translocation alone does not explain the aggressiveness of MCL nor 
is the deregulation of cyclin D1 sufficient to initiate disease progression.30 The 
t(11;14)(q13;q32) translocation has been detected in 8% of peripheral blood samples from a 
population of healthy individuals.3 Secondary genomic alterations are therefore necessary for 
malignant transformation. While the t(11;14)(q13;q32) translocation is considered a hallmark 
of MCL there is a small subset of cases with no cyclin D1 overexpression (~ 10%) that still 
present with a conventional MCL morphology and phenotype. These tumors have a gene 
expression profile almost identical to cyclin D1-positive MCL and about 50% of these cases 
express high levels of either cyclin D2 or D3 caused by chromosomal rearrangements fusing 
CCND2 or CCND3 to the IG loci.31–33 As the cyclin D1 translocation is not present in all 
cases of MCL and as immunohistochemical detection is problematic for cyclin D2 and cyclin 
D3 since these cyclins, in contrast to cyclin D1, are expressed in normal B cells and other 
lymphomas, there has been an interest in identifying other diagnostic markers for MCL. 
SOX11 has proven a valuable diagnostic tool as it is expressed in almost all MCL cases, and 
importantly it is expressed in MCL cases lacking the CCND1 translocation.34 
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1.2.4 SOX11 
The SOX11 gene belongs to the Sry-related high-mobility group (HMG) box transcription 
factor family group C, together with SOX4 and SOX12.35–37 These genes are crucial for 
organogenesis.38,39 Postnatally, SOX4 expression is restricted to B and T cells and gonad cells 
while the expression of SOX11 is primarily confined to neural tissue.40,41 The role of SOX12 
is less well described but expression has been observed across different cell types.38 Members 
of the SOXC group preferentially bind to CA/TTTGTT genomic motifs (at surprisingly low 
affinity levels compared to other transcription factors)37 via the much-conserved N-
terminally located HMG box, for which the SOXC group members share 84% identity.38 In 
lymphopoiesis, SOX4 is essential for pro-B cell survival42 while SOX11 has no known role.  
While SOX11 is silenced in nearly all mature B-cells43,44 it is expressed in over 90% of MCL 
cases and more importantly it is strongly expressed in cyclin D1-negative MCL while not 
expressed at all or at very low levels in other lymphomas.34,43 In studies focusing on distinct 
non-hematopoietic malignancies such as ovarian cancer and gliomas, it has been suggested 
to act as a tumor suppressor,45,46 while in aggressive breast cancer and head and neck cancer, 
SOX11 has been suggested to have oncogenic properties.47,48 Some studies of MCL have 
argued that SOX11 has oncogenic properties, promoting proliferation and hampering 
terminal B-cell differentiation by down-regulation of BCL6 and PAX5.49–51 The repression 
of BCL6 by SOX11 may impair MCL cell trafficking to and within germinal centers (GC). 
In a recently developed murine model with B-cell specific SOX11 overexpression it was 
shown to promote BCR signaling and proliferation.52 This is however not without 
controversy as other studies investigating the oncogenic properties of SOX11 in MCL have 
rendered contradictory results indicative of a reduced proliferative response upon increased 
SOX11 expression.53–55 Recent studies have additionally linked SOX11 to the regulation of 
functions related to tumor-supportive microenvironmental interactions, such as the migration 
of MCL cells below bone marrow derived mesenchymal cells or in promoting angiogenesis, 
suggesting that the role for SOX11 in lymphomagenesis may be context dependent.56,57 
SOX11 expression has proven a reliable tool for diagnosis of cyclin D1-negative MCL34 and 
in addition studies have begun to evaluate a presumptive prognostic role for SOX11, as 
indolent MCL cases are often negative for SOX11. This is however a controversial subject 
as several independent groups have reported that SOX11 has no independent prognostic role. 
13,15,55,58 
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1.2.5 Secondary chromosomal aberrations in MCL 
MCL commonly has a complex genetic landscape with a relatively high frequency of 
genomic abnormalities. Several chromosomal deletions and amplifications have been 
reported, and the majority of candidate genes related to the chromosomal aberrations are 
related to DNA damage response pathways, cell cycle regulation and cell survival.59 
Homozygous deletion at 9p21 is frequently observed in MCL60 affecting the CDKN2A locus 
that encodes for both the CDK inhibitor INK4a as well as the tumor suppressor ARF, which 
protects TP53 from MDM2-regulated proteasome degradation. Mono-allelic deletions are 
frequent observed at 17p and 11q, containing TP53 and ATM respectively. Amplifications 
have been reported for a number of chromosomal regions targeting MDM2 and CDK4 at 
12q13 as well as the anti-apoptotic BCL2 (18q21). Albeit rare, overexpression of the 
oncogene MYC either by amplification events at 8q24 or by other mechanisms such as the 
Burkitt translocation t(8;14)(q24;q32) has been observed in blastoid MCL cases where it has 
been correlated with a poor prognosis.61,62 
1.2.6 Somatic mutations in MCL 
The frequency of somatic mutations in MCL (1.2 per Mb)—while higher than for CLL and 
acute myeloid leukemia (AML)—is lower than for most hematopoietic and solid tumors. The 
most commonly mutated genes are ATM, TP53 and CCND1.63 ATM, which encodes for a 
protein important in cellular responses to DNA damage, is often subject to truncating or 
missense mutations in IGHV-non-mutated MCL and its inactivation has been correlated with 
increased genomic instability.64 CCND1 is frequently mutated in the indolent MCL subtype 
while TP53 mutations are equally distributed between IGHV mutated and un-mutated cases 
irrespective of SOX11 expression.63 Other notable reoccurring somatic mutations have been 
reported in the anti-apoptotic gene BIRC3, the cell surface receptor TLR2 and in the three 
chromatin modifiers WHSC1, MLL2 and MEF2B.63 NOTCH1 and NOTCH2 are among the 
less frequently mutated genes in MCL, albeit with possible prognostic importance given the 
association between mutational status and inferior outcome.63 
1.2.7 Constitutively activated pathways in MCL 
Accumulated genomic gains and losses together with somatic mutational events give rise to 
constitutive activation of several pathways in MCL. The underlying mechanism for their 
activation and the implications thereof remains to be fully understood. The cell survival-
promoting NF-κB pathway is frequently deregulated in MCL leading to an overexpression of 
several anti-apoptotic genes such as: BCL2, BCL2L1, XIAP, MCL1 and cFLIP.65 The 
mechanism for activation remains to be elucidated but signaling via the B-cell receptor 
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(BCR) pathway or via TNF-family receptors reportedly can lead to NF-κB activation.65 The 
cell-surface BCR is connected to a network of kinases and phosphatases, which have roles 
with regards to survival, differentiation and proliferation during normal B-cell maturation. 
Chronic and tonic activation of signaling via the BCR is common in B-cell malignancies. 
Several kinases downstream of the BCR such as BTK, SYK and LYN are reportedly 
phosphorylated in MCL, indicative of an activated BCR signaling pathway.66 Apart from 
observations of activated BCR signaling in MCL, emerging evidence suggests a role for BCR 
signaling in response to external stimuli in the proximal microenvironment, where, for 
instance, MCL and CLL cells residing in LN tissue have increased transcript levels of BCR 
signature genes.67,68 It has recently become more evident that anti-apoptotic signaling via the 
tumor microenvironment may play a crucial role for the onset and progression of MCL and 
other B-cell malignancies than previously anticipated. In many cases the anti-apoptotic 
signaling may derive from pathways connected to the BCR. In addition, activated, 
phosphorylated key components of the PI3K/AKT/mTOR pathway have been found in MCL 
and several differentially expressed pathway components have been observed in MCL by 
global gene expression profiling, which can promote tumor proliferation and surviva69,70 
Gene expression profiling in primary MCL samples found several components of the Wnt 
pathway, known to be deregulated in several malignancies, to be up-regulated.69 Another 
study found a transcriptionally activating form of beta-catenin present in the nucleus in MCL 
cell lines and primary samples, leading to an activated transcription of its targets, including 
cyclin D1 and MYC.71 It is interesting to note the tremendous and maybe disproportionate 
effort that has been made to describe genetic abnormalities and dysregulated pathways in 
MCL and other hematological malignancies in relation to the research that has been 
conducted in regards to the cellular context. Recent efforts have however begun to dissect 
the different effects that the microenvironmental context has on the malignant cells in studies 
comparing malignant cells of different origin (peripheral blood, lymph node and bone 
marrow) in CLL and MCL.67,68,72 
1.2.8 Treatment 
MCL is notoriously difficult to treat, virtually incurable and no therapy is considered 
standard. For disease stratification the established Mantle Cell Lymphoma International 
Prognostic Index (MIPI), which makes use of the age of the patient, the Eastern Cooperative 
Oncology group performance index, lactate dehydrogenase level and leukocyte count, readily 
discriminates between indolent and aggressive cases while the resolution for intermediate 
cases makes interpretation difficult.73 Incorporation of the Ki67 proliferation index74 has 
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further improved stratification and studies have suggested a role for the additive prognostic 
value of TP53 and SOX11 status.58 The rediscovered heterogeneity of the disease and the 
introduction of high-dose cytarabine chemotherapy combined with autologous stem cell 
transplantation (ASCT) and anti-CD20 treatment (Rituximab, a chimeric monoclonal 
antibody) have produced promising results. This and other improvements have led to a 
prolonged overall survival as well as a few MCL cases where the patients do experience long-
term disease-free survival. Several regimens are currently under clinical investigation for 
management of different MCL patient groups. The choice of first line treatment depends on 
the age of the patient as well as fitness status. Young, fit patients may benefit from a high 
dose, R-CHOP/R-DHAP (R-CHOP: cyclophosphamide, doxorubicin, vincristine and 
prednisone in combination with Rituximab; R-DHAP: dexamethasone, high-dose cytarabine 
and cisplatin in combination with Rituximab) treatment combined with an ASCT while unfit 
younger patients or fit elderly patients may be treated with conventional regimens such as 
standard dose R-CHOP or R-BAC (bendamustine and cytarabine in combination with 
Rituximab) followed by Rituximab maintenance.75 Unfit and frail elderly patients require a 
less toxic immunochemotherapy treatment combined with Rituximab, followed by 
Rituximab maintenance. For patients presenting with an indolent disease manifestation; 
watch and wait until the disease advances is recommended, followed by therapy as 
conventional MCL upon disease progression. Relapsing MCL patient’s response rates are 
generally lower regardless of choice of regimen. While some younger patients can respond 
well to second-line therapy the only treatment associated with long-term remission is the 
ASCT. Treatment of elderly or unfit patients that can no longer withstand chemotherapy and 
much less an ASCT calls for a palliative approach. 
Recent findings have increased the hope that individualized medicine and small molecules 
targeting specific pathways will improve survival further. Two small molecules are currently 
being tested and integrated into conventional regimens for treatment of MCL and CLL, the 
proteasome inhibitor Bortezomib and the Bruton’s tyrosine kinase (BTK) inhibitor 
Ibrutinib.76,77 Bortezomib reversibly inhibits the proteolytic activity of the ubiquitin-
proteasome system and Ibrutinib is an orally administrated small molecule that covalently 
binds to and inhibits BTK activity. Interestingly, a phase 1 study found an increase in CD19+ 
CD3- CD5+ cells in the peripheral blood of MCL patients following ibrutinib treatment,78 
indicative of a function for BCR signaling in relation to microenvironmental interaction and 
retention that could possibly be exploited to expel cells from tumor-harboring niches to the 
peripheral blood where they can more readily be targeted by other targeted therapy strategies 
or even by conventional chemotherapy regimens. Ibrutinib has also been shown to inhibit so 
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called pseudoemperipoesis (migration of cells below a stromal cell monolayer), in a CXCR4 
dependent manner, using an in vitro co-culture system with a MCL cell line and mesenchymal 
stromal cell line.78 Recently, the second generation BTK inhibitor Acalabrutinib was 
approved for treatment of refractory MCL, reportedly more specific to BTK than Ibrutinib, 
reducing off target effects, and with more potent in vivo activity.79–81 
Other promising drugs in early phase clinical trials for treatment of MCL include the second-
generation BCL2 inhibitor Ventoclax82, a CDK4/6 inhibitor,83 inhibitors of histone 
deacetylases as well as an anti-CD79 conjugated monoclonal antibody.84 Additionally, the 
immunomodulatory small molecule lenalidomide has recently been approved for treatment 
of relapsed MCL by the FDA based on positive overall response rates in multiple phase II 
studies.85,86 While targeting the anti-apoptotic BCL2 in MCL may pose a viable option, 
concerns arise as other BCL2 family members, such as MCL1 and BCL2L1 (encoding for 
Bcl-xL), have been shown to be up-regulated in response to signaling from proximal cells in 
vitro,87,88 and increased mRNA levels of these two anti-apoptotic proteins have been observed 
in LN material as compared to peripheral blood in MCL.87 
1.3 MYC IN LYMPHOMAS 
The transcription factor MYC (encoded by MYC and sometimes referred to as c-Myc) is a 
basic helix-loop-helix protein that together with the paralogues MYCN, and MYCL 
constitutes the MYC family of transcription factors, all with similar structural and functional 
properties albeit with different expression across different tissues that have been implicated 
in the development and progression of a substantial fraction of human tumors. For the present 
discussion the focus will be on MYC. MYC has its name from its viral oncogenic homolog 
v-myc of the avian myelocytomatosis virus (MC29).89–92 Its expression is essential during 
embryogenesis and a gene knock-out is embryonically lethal in mice.93 Expression of Myc is 
important for the survival of B-cell precursors and their subsequent differentiation into 
mature B-cells and Myc expression can be detected at both pro- and pre-B-cell stages in 
mouse.94,95 Mature, resting murine B-cells express MYC at very low levels.95 MYC is 
expressed in a subset of GC B-cells and it is required for GC formation and maintenance.96 
In the GC increased MYC levels upon repression of its repressor BCL6 in the light zone 
allows for entry into the dark zone and somatic hypermutation reactions. Later, upon exiting 
the GC, MYC transcription in the B-cell is repressed by BLIMP1, allowing for differentiation 
into plasma cells.97 MYC was early found to be translocated to the immunoglobulin heavy 
chain locus (t8;14)(q24;q32) in Burkitt’s lymphoma cells, an event that leads to deregulated 
expression.98,99 In 10-15% of Burkitt’s lymphoma cases MYC is instead juxtaposed to either 
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the Igk (2p12) or Igl (22q11) immunoglobulin genes, which similarly leads to aberrant 
expression and a Burkitt’s lymphoma phenotype.100,101 A deregulated MYC expression is 
however not sufficient for malignant transformation and secondary mutational events are 
necessary to overcome responses that would otherwise lead to apoptosis or senescence.102–
104 More recently, and relevant for the present thesis, a study found that oncogenic 
transformation of murine B-cells was only possible if both intrinsic apoptosis and a TP53 
dependent response were circumvented by the overexpression of BCL2L1 and BMI1 in 
conjunction with MYC.105 Chromosomal rearrangements leading to the juxtaposition of 
MYC to the heavy chain locus have also been reported in 5-10% of DLBCL cases and the 
rearrangements have been associated with a poor prognosis.106–108 In rare cases, the 
translocational event leading to aberrant MYC expression has also been observed in MCL 
where it, as in DLBCL, has been associated with an adverse prognosis.109 Across aggressive 
B-cell lymphomas however, there are cases with elevated MYC levels irrespective of the 
chromosomal aberrations mentioned above, indicative of other mechanisms leading to 
increased MYC levels and cell transformation.110 In MCL for example, increased MYC levels 
resulting from amplification events have been associated with a poor prognosis.111 Across a 
variety of human cancers, the most frequent amplification events are those affecting 8q24 
where the MYC gene is located.112 Additionally, albeit rare, increased MYC levels due to 
translocation in CLL are associated with a poor prognosis.113 
1.3.1 MYC structure, protein stability and mutational landscape 
The MYC protein consists of a C-terminally located basic helix-loop-helix leucin zipper 
(bHLH-LZ) domain used for heterodimer formation with other bHLH-LZ transcription 
factors such as MAX and ZBTB17 (gene product also known as Miz-1) via the basic region 
located N-terminal to the HLH-LZ to bind DNA. The N-terminally located trans-activation 
domain (TAD) contains stretches of conserved regions entitled Myc box 0–IV (MB0–IV) 
where the MBI contains a proline-rich stretch of residues important for MYC activity and 
stability, where mutations frequently are found in lymphoma patients.114–116 
Sequential phosphorylation of MYC at serine 62 and threonine 58 by ERK/CDK2 and 
GSK3b respectively, first activates MYC, and subsequently primes it for proteasomal 
degradation, summarized by Amy S. Farrell and Rosalie C. Sears.117 The most frequent 
mutation found in lymphoma is T58I while the somewhat less frequent T58A is associated 
with protein stabilization and higher transforming capacity.118 The half-lives for WT MYC 
and T58I are around 30 min while the T58A half-life is double that,118 which is intriguing 
given removing the phosphorylation site at T58 is not the sole contributor to increased protein 
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stability but also properties of the residue such the effect it has in regards to phosphorylation 
at S62, which is impaired in T58I.119 The T58A substitution has additionally been shown to 
promote a more rapid tumor development in mice as compared to WT MYC.116,120 Gene 
regulation differences for MYC variants differing at T58 have been reported using fibroblast 
model systems with hundreds of genes reportedly differentially regulated between MYC WT 
and MYC T58I expressing cells.118 How the mutational status affect gene expression in a 
more relevant, lymphoma-like system remains to be investigated and is addressed by the 
present thesis. 
1.3.2 Genome recognition and gene regulation by MYC 
MYC has a central role for transcriptional regulation of genes involved in many fundamental 
cellular processes such as growth, cell division and apoptosis. It can form heterodimers with 
MAX to bind DNA canonical E-box motifs (CACGTG) or variants thereof to, directly or 
indirectly, regulate the expression of a vast number of genes. While the MYC/MAX 
heterodimer has the highest affinity for the canonical E-box,121,122 which, incidentally, is one 
of the most frequent motifs in the human genome.123 MYC/MAX has additionally been 
shown to bind non-canonical E-boxes as well as  genomic sequences without recognizable 
E-box motifs.122,124 The progressive affinity for different genomic motifs allows for specific, 
MYC-level dependent regulation of sets of genes where those with high affinity canonical E-
box motifs are occupied preferentially, sequentially followed by motifs with lower and lower 
affinity, with the capacity to regulate the associated genes.125 The MYC has also been shown 
to repress the expression of sets of genes through interactions with ZBTB17 (also known as 
MIZ1),126,127 later studies have questioned this as mutated MYC, unable to interact with 
ZBTB17,  retained repressive capabilities and an additional role for ZBTB17 where it may 
affect MYC-promoted RNA polymerase II recruitment.128 This simplified description of the 
regulatory involvement of MYC is probably misrepresentative as the role of MYC is 
pluralistic, given its multiple interaction partners and seemingly diverse involvement in 
functions like proliferation, growth and apoptosis. Additionally, MYC was one of four genes, 
alongside Sox2, Klf4 and Oct4 that could reprogram and de-differentiate fibroblasts into 
pluripotent stem cells and it is crucial for hematopoietic stem cell maintenance and 
survival.129,130 There is currently little evidence for transcriptional regulation of specific 
genes being the only, or even the primary function, of MYC for propagating oncogenic 
responses, as pointed out in a review by Wolf et al.131 MYC has for instance been shown to 
promote transcription by both RNA polymerase I132 and III,133 to promote the interaction 
between the rDNA and the nucleolar matrix via the intergenic spacer regions,134 and has been 
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shown to release RNA polymerase II from transcriptional pausing.135,136 Interestingly, MYC 
has been shown to bind to the promoter region of genes to elevate the transcription of all 
accessible genes, which led to the hypothesis that MYC is a global transcriptional 
amplifier.137,138 This is however not a likely sole explanation model given the specific and 
context dependent gene regulation by MYC described more recently127,128,139 and given the 
gradual specificity the MYC/MAX heterodimer shows for canonical E-box motifs and 
similar variants.122,125 Additionally, direct expressional regulation of specific genes by MYC 
has recently been shown in a model system where the de novo transcription of a particular 
set of genes was shown to decrease upon rapid MYC degradation, several of these genes were 
directly involved in functions such as ribosome biogenesis and purine synthesis.140 
Interestingly, the identified signature of genes directly regulated by MYC was collectively 
increased at the mRNA level in data sets derived from a diverse set of human cancers in 
relation to the measured levels of MYC. Based on these recent findings a more plausible 
unified explanation model has been put forth where MYC specifically regulates subsets of 
genes based on promoter affinities while promoting transcription of accessible genes, the net 
effect being a significant increase in transcription of genes where MYC has the highest 
promoter affinity making it a non-linear amplifier of expression. This should however be 
context dependent and in cases where MYC levels are high, and high-affinity promoters 
saturated, the net effect could be increased expression of genes with lower promoter affinity 
for MYC. 
1.4 THE TUMOR MICROENVIRONMENT 
1.4.1 General implications of the tumor microenvironment 
While tumors arise due to somatic mutations and genetic aberrations promoting clonal 
expansion and a growth advantage for the transformed cells, the events do not occur in 
isolation but within a complex tissue context, often involving multiple cell types. Over the 
past decades it has become increasingly evident that the microenvironment plays a vital role 
for tumor expansion, vascularization, metastasis and drug resistance. When Hanahan and 
Weinberg revised their “hallmarks of cancer“141 in 2011 the effect that the tumor stroma has 
on the malignant cells was given substantial space and microenvironmental implications were 
discussed for every hallmark.142  It is now widely appreciated that solid and hematopoietic 
tumor cells do not act in isolation nor as a homogenous cell-cluster but rather engage in a 
dynamic crosstalk with proximal and distal cellular components within the organism. A 
malignant lesion may therefore be seen more as an organ where both tumor and normal cell 
composition constitute important components for cancer initiation, growth, progression and, 
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as will be discussed further on, resistance to therapy. Several components of the tumor 
stroma, in the form of secreted molecules, adhesion molecules or surface receptors and their 
interactions with the malignant cells have been identified both as presumptive therapeutic 
targets as well prognostic markers for disease stratification. 
Different cell-types frequently infiltrate and interact with malignant cells in the tumor tissue. 
These recruited or invading cells may be implicated in a diverse repertoire of pro tumorigenic 
mechanisms and can for instance: act to promote proliferation, confer resistance to cell death, 
evade destruction by the immune system or act to promote metastasis. Endothelial cells may 
infiltrate tumor tissue in response to vascular growth factors such as VEGF and FGF and see 
to the vascularization of the lesion together with pericytes. Cancer associated fibroblasts 
(CAFs) have been extensively studied in solid tumors over the past decade and are known to 
produce growth factors like TGF-β, EGF and HGF, mitogenic factors such as SFRP1 and 
IGF1 as well as chemokines like CXCL12 and CXCL14.143 The CAF is thought to be a 
locally recruited fibroblast educated by the tumor environment to produce growth-promoting 
signals. Cytokine gradients of CXCL12, CXCL14 and others serve to recruit immune cells 
such as macrophages and B-cells to the lesion, reshaping the microenvironmental 
composition. Together with other microenvironmental signals they can polarize the 
recruitment of immune cells favoring an immune-dampening response where M2 
macrophages and Th2 cells are attracted to the tumor tissue. 
Infiltration of pro-tumorogenic immune cells into the tumor tissue is frequently observed in 
both solid and hematopoietic malignancies. Regulatory T and B cells (TReg, Breg) can provide 
mitogenic stimuli to tumor cells while locally reducing immune responses by, for instance, 
suppressing cytotoxic T cells whose presence in tumors have been correlated with a favorable 
disease outcome in several malignancies.144 
1.4.2 The tumor microenvironment in B-cell malignancies 
Lymphoma cells often occupy natural B-cell niches such as the bone marrow or the lymph 
node, but different lymphomas have different relations to their immediate microenvironment, 
both in terms of microenvironmental dependencies and the capacity to recruit or re-educate 
proximal cells. Hence, the composition of the tumor microenvironment varies between B-
cell malignancies.145 In BL the lesions consist almost exclusively of autonomous, malignant 
cells with few, if any dependencies in regards to the microenvironment while, in contrast, the 
structure of the tumor tissue in FL is more reminiscent of normal lymphoid structures where 
the malignant cells take advantage of niches normally important for the survival and 
proliferation of non-malignant B-cells. In classical Hodgkin’s lymphoma the infrequent 
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malignant cells are supported by a large stromal component, distinct from normal tissues, 
where supportive cells have been recruited to shape the microenvironment. Other lymphomas 
have microenvironmental dependencies that fall somewhere in between these more extreme 
cases. In FL and DLBCL, different compositions of non-malignant cells within the tumor 
stroma, such as infiltrating non-malignant immune cells have been correlated with survival, 
which further underlines the importance of the tumor microenvironment in lymphoma 
progression.146,147 In MCL, infiltrating T-cells have been ascribed prognostic properties.148 
Normal B-cells are harbored by and dependent on niche-specific signaling in different 
microenvironmental settings during their differentiation and maturation process. These 
signaling mechanisms are not random but precisely regulated, intrinsically through regulation 
by stage-specific transcription factors and in response to external stimuli. As the immediate 
environment is of great importance for B-cell homing and differentiation the notion and 
composition of the tumor microenvironment B-cell neoplasms is therefore inherently 
different from the microenvironment in most solid tumors. Malignant B-cells can make use 
of signaling mechanisms intended for their non-malignant counterparts as survival-
promoting pathways are often functional in the malignant cells.149 Lymphoma cells can also 
make use of surface molecules for accessing niches through migration towards normally 
occurring gradients of chemokines. This has for example been illustrated by knock-out 
studies of the CCR7 surface receptor in the Eµ-Myc mouse model where CCR7-deficient 
mice were tumor free significantly longer than wild type and as B-cells from the two 
genotypes were subsequently transplanted into congenic mice the CCR7 deficient B-cells 
infiltrated LN, Spleen and bone marrow (BM) tissue slower and to a significantly lower 
extent.150 Similar homing functions allow for interactions with mesenchymal stromal cells, 
lymphoma associated macrophages and regulatory T-cells among others and are implicated 
in immune evasion, proliferation and anti-apoptotic responses. Evasion of the immune 
system can be mediated by several mechanisms such as down regulation of MHC class II 
molecules, simultaneous down regulation of MHC I and CD58, which obliterates the effects 
of both CD8+ T-cells and neutrophils, by increased expression of CD95L which induces 
apoptosis in CD8+ T cells or via recruitment of cells with an immune dampening effect such 
as TReg or BReg cells. Interestingly, recent studies in CLL have shown that the malignant cells 
themselves can act in a regulatory fashion given right external stimuli.151 
There is a growing appreciation for the BM as a survival-promoting niche for malignant B-
cells in hematological cancers such as CLL and MCL, these cellular interactions may 
ultimately be responsible for the development of the phenomena referred to as minimal 
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residual disease. Even though the bulk of the malignant cells can often be efficiently 
eradicated by ever evolving and constantly refined chemotherapy regimens a minority of the 
malignant cells can still be protected by, for instance, niches of the BM. These surviving cells 
subsequently have the capacity to expand and repopulate the patient upon treatment 
termination. A better understanding of the overlap and differences between hematopoietic 
stem cell-homing and a presumptive cancer stem cell niche will therefore be of use when 
therapeutically targeting the tumor microenvironment. 
Primary MCL and CLL can only be kept in culture for a few days before they undergo 
spontaneous apoptosis.152,153 If co-cultured with mesenchymal stromal cells on the other 
hand, the in vitro cultures can be sustained for months.153,154 The anti-apoptotic effect has 
been associated with an adhesion-mediated increased signaling via the canonical and non-
canonical NF-κB pathway in the malignant cells leading to increased levels of the anti-
apoptotic proteins BCL2L1 and MCL1.87,88,153,155  
At diagnosis MCL patients frequently present with a disseminated disease often involving 
multiple extranodal tissues. Consequently, in MCL patients, several distinct 
microenvironmental niches exist that supposedly have different ways of supporting the 
lymphoma cells. An explanation for the frequent relapses in MCL may be the homing of a 
subpopulation of cells in survival-promoting, protective microenvironments where 
interactions between MCL cells and the stroma allow for treatment evasion and pave the way 
for minimal residual disease. While recent studies have brought forth questions related to the 
microenvironment in MCL much remains to be elucidated in regards to the effect that the 
different genomic abnormalities in MCL have on the cells capacity to interact with and shape 
their immediate microenvironment. In a recent review by Puente et al.156 aiming to discuss 
genetics of MCL and CLL in relation to each other and to the microenvironment partially 
fails due to the strong focus on the genetic component, almost entirely omitting to discuss 
the cellular context. 
The G-protein coupled surface receptor CXCR4 is important for homing and migration of B-
cells to the bone marrow or to/within secondary lymphoid structures,157–159 it is expressed at 
multiple instances during development.160 Surface expression of CXCR4 allows for 
migration towards CXCL12 gradients, which is secreted by cells in the microenvironment 
such as stromal cells. Knocking out either the CXCR4 receptor or its ligand, the chemokine 
CXCL12, are both lethal in mice.161162 MCL and CLL cells reportedly express high levels of 
the CXCR4 surface receptor which can be utilized to access supportive microenvironmental 
niches.163,164 Additional surface receptors for chemoattractants important for B-cell homing 
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and migration are CXCR5, which is the receptor for CXCL13, as well as CCR7 which has 
been shown interact with CCL19 and CCL21 and more recently also with CXCL12.165 
CXCL12, in addition to promoting migration to protective niches, also has a direct role in 
promoting cell survival in CLL by reducing apoptotic responses.166 Small molecules such as 
the agonist Plerixafor have been developed, which upon binding to CXCR4 leads to receptor 
internalization without triggering downstream signaling.167 Plerixafor has been shown to 
expel different hematopoietic cells of both human and murine origin from tissues into the 
peripheral blood.168,169 In MCL, inhibition of CXCR4 by plerixafor has been shown to impair 
migration of MCL cells beneath stromal cells.163 Additionally, reduced CXCR4 surface levels 
have been reported in LN residing cells in MCL and CLL as compared to those in 
circulation.67,78 
In the GC, interactions between B-cells and adjacent cells via ICAM1 or VLA-4, have been 
shown to decrease the number of apoptotic cells.170 MCL cells frequently express high levels 
of VLA-4.163 Signaling via VLA-4 can promote cell survival of NHL cells171 and has been 
implicated in cell adhesion mediated drug resistance and the protective effect provided to the 
MCL cells by proximal stromal cells can be overcome by directly targeting the VLA-4 
surface molecule by antibodies.172 ICAM1 is commonly expressed on B-cells and facilitates 
their exit from circulation by enabling adhesion to the vascular wall.173 High ICAM1 levels 
have been observed in a subset of MCL patients174 and in CLL, ICAM1 surface expression 
and plasma levels have been corelated with clinical stages of CLL.175 
MCL cells express the surface receptor CD40, permitting proliferation and survival support 
by CD154+ T cells. In vitro experiments have shown a proliferative response in MCL upon 
stimulation with the CD40 ligand CD154 and a study of several B-cell malignancies that 
included a few MCL cases, found that infiltration of TReg cells could provide similar stimuli 
via the CD40-CD154 axis.176–178 Infiltration of macrophages into the tumor tissue has been 
observed in aggressive MCL cases with increased mitotic activity, their role is yet to be 
investigated but may be similar to lymphoma associated macrophages which have been 
described and correlated with an inferior prognosis in FL.179–181 
1.4.3 The B-cell receptor and the microenvironment in MCL 
A constitutively active signaling via the BCR has been reported in MCL cell lines and patient 
samples66 and interestingly, studies using primary material from CLL and MCL patients have 
identified the increased expression of BCR genes in cells in the LN when compared to those 
in the peripheral blood.67,68 Consistently, the observed exodus of cells from lymphoid tissues 
in MCL patients treated with the BTK inhibitor Ibrutinib further supports the importance of 
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BCR signaling for the homing of lymphoma cells.78 Interestingly, in vitro studies using MCL 
cell lines have shown that BTK inhibition by Ibrutinib has been shown to reduce migration 
towards both CXCL12 and CXCL13 gradients.78 While interacting antigens and the 
underlying mechanism has not been determined, constitutive activation of Syk, PKCβ-II and 
PI3K, all downstream of the BCR, have been reported in MCL.182–184 The activated BCR 
signaling leads to downstream activation of the NF-κB and MAP kinase pathways among 
others, promoting survival, for instance resulting from increased levels of the anti-apoptotic 
proteins BCL2L1 and MCL1, as well as cell division. While the microenvironmental 
mechanisms promoting activation of BRC signaling have yet to be elucidated the therapeutic 
potential remains high given the promising responses in clinical trials targeting central actors 
downstream of the BCR with small molecules. 
1.4.4 Environment mediated drug resistance 
So far, the discussion here has focused on how neoplastic B-cells take advantage of homing 
signals from the tumor microenvironment for direct growth support, survival and immune 
evasion. Accumulating evidence also suggests that intercellular interactions in the tumor 
microenvironment can alter the tumor cells sensitivity to chemotherapeutic agents. The 
special case of environment mediated drug resistance called cell adhesion mediated drug 
resistance (CAM-DR) was first described in myeloma cell lines.185 Ex-vivo studies of MCL 
cells have shown that interactions with stromal cells can make the malignant cells less 
susceptible to cytotoxic treatment, partly through induction of the NF-κB pathway.153 
Notably, cells that did not adhere to the stromal cell monolayer were still sensitive to drug-
induced apoptosis while soluble factors, such as the B-cell activating factor (BAFF)—
produced by stromal cells upon contact with lymphoma cells—lowered the apoptotic 
effect.153 Reports of similar effects have been observed in CLL, where a number of different 
stromal cell lines have been shown to protect CLL cells.186 Additionally, direct interactions 
between lymphoma cells and stromal cells have been shown to induce cell cycle arrest in 
MCL and DLBCL, making the malignant cells less susceptible to cytotoxic agents aimed at 
proliferating cells.187 The mechanisms and underlying microenvironmental cross talk giving 
rise to CAM-DR, survival of the malignant cells and subsequent relapse in patients remain 
to be fully characterized. 
1.4.5 Therapeutic targets in the MCL microenvironment 
Several approaches have been undertaken to target tumor-promoting microenvironmental 
interactions in MCL and here follows a brief description of four options that are or may 
develop into options for treatment of MCL. CXCR4 inhibitors such as Plerixafor have been 
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shown to disrupt homing signals and mobilize tumor cells into peripheral blood in both 
hematological and solid malignancies.188 When deprived of protective signals from the 
microenvironment these cells can more efficiently be targeted by conventional 
chemotherapy.189 As hematopoietic stem cells make use of the very same signaling for 
homing a combinatory treatment with molecules specifically targeting the malignant cells is 
desirable. In general, the issue with overlapping signaling mechanisms between cancer stem 
cell niches and hematopoietic stem cell niches will have to be addressed to efficiently target 
the tumor microenvironment while keeping toxicity low. The need for a better 
characterization of the different supportive signaling mechanisms cannot be emphasized 
enough and recent studies of global gene expression differences in MCL and CLL cells 
residing in different microenvironmental contexts have begun to identify presumptive targets 
that are important for intercellular communication and physical interactions. 
Therapeutic targets in the tumor microenvironment include adhesion molecules such as 
VLA-4, which is frequently expressed in MCL and can be targeted by the humanized 
monoclonal antibody Nataluzimab163 
Blocking signaling through the BCR via the BTK inhibitor Ibrutinib has produced promising 
results, mobilizing MCL cells from lymphoid tissue into the peripheral blood where they can 
be targeted by conventional therapy.78 Ibrutinib has in addition been shown to impair 
migration and survival in CLL cells as well as their ability to secrete BCR dependent 
chemokines such as CCL3 and CCL4, both thought to promote interactions with T cells.190 
This underlines a central role for the BCR when it comes to migration and homing. The 
second generation BTK inhibitor Acalabrutinib reportedly have a higher specificity for its 
target and reports following a phase-2 trial in patients with relapsed or refractory MCL have 
shown promising results.80,81 Targeting other central components of the BCR signaling 
pathway like Syk may have potential and the small-molecule Syk-inhibitor R406 has shown 
promising results in both pre-clinical studies and in a first clinical trial in CLL.191
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2 AIMS 
The overall aim of the thesis was to establish and study relevant model systems for 
investigating the implications of intrinsic and extrinsic stimuli of cells in lymphomagenesis. 
Specifically, the studies aimed to do the following: 
2.1 PAPER I 
Given that stromal cells of different origin can protect MCL and CLL cells from drug-induced 
apoptosis the aim of Paper I was to develop and characterize a model system for studying 
cellular changes arising in lymphoma cells upon interaction with and/or attachment to stromal 
cells. 
2.2 PAPER II 
Based on findings from Paper I the aim of Paper II was to evaluate the findings from Paper I 
in a similar albeit different model system and investigate to investigate the extent of common 
and divergent effects in response to MCL cell adhesion to stromal cells. 
2.3 PAPER III 
The aim of paper III was to investigate the effect of SOX11 overexpression in the non-
malignant pre-B-cell Ba/F3, in order to determine whether it showed oncogenic activity. 
2.4 PAPER IV 
In Paper IV the aim was to develop a model system for testing the effect of progressively 
increasing MYC levels in B-cell lymphomagenesis and characterize the differences between 
wild type MYC and two lymphoma-associated MYC mutants under these circumstances, in 
order to determine the role of wild type and mutant MYC in the conversion of normal B-cells 
to lymphoma cells. 
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3 METHODOLOGICAL CONSIDERATIONS 
Here follows a brief discussion of technical and methodological considerations and choices. 
Full descriptions of the materials and methods are available in the respective publications. 
3.1 CELL SOURCES 
For studies of microenvironmental interactions in MCL, two well-characterized MCL cell 
lines that grow in single-cells suspensions were chosen: JeKo-1 was established in 1998 from 
mononuclear cells of the peripheral blood from a 78 year old female patient diagnosed with 
MCL.192 The rendered cell line had a B-cell phenotype expressing cell surface markers: IgM+, 
IgD+, CD3-, CD5+, CD10-, CD19+, CD20+ and CD23- and carried the MCL-associated cyclin 
D1 translocation t(11;14)(q13;q32). The JeKo-1 cells used in the present studies were 
purchased from the DSMZ. Rec-1 was established in 1988 from lymph node material from a 
61 year old male patient with malignant large-cell B-lymphoma positive for 
the t(11;14)(q13;q32) translocation, which had the following cell-surface characteristics: 
IgM+, IgD+, CD3-, CD5-, CD10-, CD19+, CD20+, CD22+, CD23- and CD37+.193,194 The Rec-
1 cells used here were a kind gift from Dr. Christian Bastard, Ronan, France. 
Recent studies have shown that an array of different stromal cell lines, of both human and 
murine origin, can protect lymphoma cells from undergoing both spontaneous and drug-
induced apoptosis. 153,163,172,186,195 MS-5 is a bone marrow derived murine stromal cell line 
established in 1988 that has the capacity to support the growth of hematopoietic stem 
cells.196,197 It was chosen for its documented capacity to protect lymphoma cells from 
spontaneous and drug-induced apoptosis153,171,195 as well as for its murine origin, which 
would later allow for transcript discrimination between the lymphoma and stromal 
components in the adherent co-culture fraction by next generation sequencing and species-
based read separation. The MS-5 cells used in the present study were purchased from the 
DSMZ. 
For investing a presumptive role for the transcription factor SOX11 in non-malignant B-cells 
in terms on the effect it has on global gene expression, proliferation and presumptive 
oncogenic transformation we transduced the murine, bone marrow derived, pro-B cell line 
Ba/F3 with a Tet-On construct that allowed for doxycycline-regulated overexpression of 
SOX11.198,199 Ba/F3 has previously been used to investigate oncogenic properties of 
proteins.200–203 
For investigating the role of MYC in its WT form or in variants carrying lymphoma-
associated missense mutations leading to the exchange of threonine 58 to either alanine 
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(T58A) or isoleucine (T58I), murine B-cells carrying Tet-On MYC constructs (WT, T58A 
and T58I) were generated through retroviral transduction of splenic B-cells with constructs 
for regulable expression of MYC and constitutive expression of BMI1 and BCL2L1 as 
described previously.204 The expression of WT MYC or mutated MYC could be regulated 
from low levels to being overtly over-expressed by adding doxycycline (in the range of 0-
1000 ng/ml) to the transformed B-cells. 
3.2 CO-CULTURE CONDITIONS AND CHARACTERISATION 
MCL cells were maintained in RPMI1640 supplemented with 10% heat inactivated FBS and 
1% penicillin/streptomycin. The MS-5 stromal cells were cultured in aMEM supplemented 
with 10% heat inactivated FBS, 2mM sodium pyruvate and 1% penicillin/streptomycin. The 
co-cultures were cultivated as the MS-5 stromal cells. The stromal cells were seeded in 
advance followed by the addition of MCL cells 24 hours later at a 10:1 MCL to stromal cell 
ratio. For quantitation of bound MCL cells the cells were labelled prior to co-cultivation using 
the Carboxyfluorescein succinimidyl ester (CFSE, CellTracer life technologies) in 
conjunction with previously labeled far red stromal cells. The ratio of bound MCL cells to 
stromal cells was determined by flow cytometry using a MACSQuant Analyzer 10 instrument 
and the data was analyzed using FlowJo (v10). 
3.3 NGS LIBRARY PREPARATION AND SEQUENCING 
For all RNA-seq experiments in the thesis, total RNA was extracted using the RNeasy kit 
(Qiagen), quality was assessed by TapeStation and subsequent cDNA libraries were created 
using the TrueSeq 2.0 library preparation kit from Illumina including a poly-A enrichment 
step by poly-T attached magnetic beads. The libraries were sequenced using different 
Illumina sequencing platforms depending on the experimental prerequisites in terms of read 
length, read count etc., e.g. the MiSeq platform was used for initial pilot experiments for 
species-based read separation for its cost-effectiveness and for the subsequent co-culture 
experiments a HiSeq2000/2500 instrument was used generating 2x101 base pair (bp) paired-
end reads. The same platform was used for global gene expression assessment in MYC over-
expressing cells, but in that study a paired-end approach was deemed unnecessary and the 
libraries were sequenced to generate 50 bp single-end reads. 
3.4 NGS ANALYSIS 
Most processor- and memory-intensive computational processes such as species-based read 
separation, alignment to reference genomes and per feature read quantification were 
conducted using the UPPNEX computer cluster infrastructure which is a member of the NIBS 
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infrastructure for bioinformatics and is a part of the UPPMAX and it is partially funded 
through the SNIC computational infrastructure for Swedish universities. Hence, all data 
processing, from quality assessment through alignment to the reference genomes and 
subsequent per-feature read-quantification was conducted in a Unix/Linux environment 
using dedicated, open-source software packages for reproducibility purposes. 
3.4.1 Read quality and pre-processing 
Quality assessment of the raw fastq data files was conducted using FastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Adapter trimming was in 
most cases automatically performed immediately following sequencing by means of Illumina 
proprietary software. A subsequent quality-based trimming of read-ends using phred scores 
was conducted using Trimmomatic.205 
3.4.2 Reference genomes 
Reference genomes for alignment-based read quantification or species-specific read 
separation were initially acquired via the UCSC (unmasked hg19 and mm10 including 
scaffolds for human and mouse respectively). Following the release of the updated human 
reference genome in December 2013 by the Genome Reference Consortium new versions of 
unmasked genomes for both human and mouse, including scaffolds, were downloaded from 
the ENSEMBL ftp server and used for subsequent analysis (GRCh38.87 and GRCm38.87 for 
human and mouse respectively). 
3.4.3 Species-based unmixing of short reads 
Given the dual cell components in the co-cultures (human MCL cells co-cultured with murine 
stromal cells) and due to the fact that lengthy physical cell separation procedures have been 
shown to introduce artifacts affecting the expression levels of genes due to sample 
preparation procedures,206–209 a decision was made to circumnavigate this by extracting total 
RNA from a mixed population of human and mouse cells followed by library preparation, 
sequencing and a subsequent in silico de-convolution of the short reads based on species 
origin. 
Initially, a method for linear unmixing of reads based on their species origin was developed 
where a per-gene bleed over coefficient was calculated, using mono-cultured human and 
murine cells, which was subsequently used for per gene unmixing. The method had several 
drawbacks. First, it assumes that the global blead over between organisms is small. This was 
not an issue in the case of the present study as the long, paired-end reads readily differentiated 
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between the two species fractions for the majority of genes. Secondly, estimation of the 
constants for the linear unmixing model had to be determined empirically, something that 
was feasible in the case of the present study but that would be more difficult in other model 
system settings such as xenografts should the method be developed further and distributed 
for broader use. Lastly, the unmixing is done at the count level using aligned and quantified 
read count data. A method capable of classifying a read based on its inherent sequence 
information prior to counting would be preferable. The species-based and publicly available 
classifying tool for short read sequencing data named Xenome met all of the criteria 
mentioned above.210 Initially developed for the deconvolution of NGS reads of xenograft 
origin Xenome uses a k-mer based approach for a mere classification of reads from mixed 
libraries of up to two species. During the indexing step a k-mer hash array based on the 
reference genomes fasta files is created which is thereafter used to classify each read as being 
derived from one or the other, neither or both of the different species. As indicated in the 
paper by Conway et al.211 the drawback of an alignment-based method using a short read 
aligner such as Tophat with read processing software like SAMtools212 is not so much the 
miss classification of reads but that a significant proportion of the reads cannot be assigned 
to either of the species exclusively which inflates the “both” category. Another approach 
would have been to use a k-mer based count approach omitting alignment such as the one 
employed by the program Sailfish.213 During the course of the project other approaches for 
species-based read separation with marginally better performance than Xenome have been 
put forward.214 Based on empirical benchmarking against the linear-unmixing approach 
(Figure 1) and the ease of use, the Xenome approach was employed in Paper I and Paper II 
using the default k-mer length of 25. 
 
Figure 1. Comparison of in silico, species-based deconvolution of short read libraries by linear unmixing (x-axis) 
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3.4.4 Alignment of short reads to the reference genome 
Reads separated based on species origin were aligned to the respective reference genomes 
using splice-aware short read aligners. For paper I we made use of Tophat2,215 which is a 
splice-aware aligner based on Bowtie2 that in turn employs a suffix-array-like so-called FM-
index which is based on the burrows wheeler transformation216 and therefore leaves a small 
memory footprint making it suitable for local desktop machines.217 It is however processor 
intensive and the alignment is time consuming despite the possibility of multi-threading. 
While the precision of Tophat2 is only slightly inferior to more recently developed short read 
aligners,218 the slow alignment process made us switch to the more recent, faster and more 
precise, splice-aware short-read aligner STAR219 for the subsequent projects. STAR, like 
Tophat2, employs a suffix-array-based approach but in contrast to Tophat2 it loads the entire 
uncompressed suffix array into the RAM memory making it memory intensive but extremely 
fast while retaining mapping precision.218 For comparison a typical fastq file that Tophat2 
would align in 4 h using < 16 GB memory STAR would align in 15 min using ~ 80 GB of 
memory. 
3.4.5 Read quantification and differential expression 
In Paper I, Reads per feature (concatenated exons for one gene) were counted using the 
Bioconductor package GenomicAlignments (1.0.6) with the counting mode set to “Union” 
with gene annotations from the Bioconductor packages 
TxDb.Hsapiens.UCSC.hg19.knownGene (v.2.14.0) and 
TxDb.Mmusculus.UCSC.mm10.knownGene (v.2.14.0). For the subsequent studies reads per 
feature were derived using the function featurecounts from the subread package in 
conjunction with gtf gene annotation files downloaded from the ENSEMBL ftp server 
(GRCh38.87 for human and GRCm38.87 for mouse). The TxDb databases contain 
information for 23459 and 24421 genes for human and mouse respectively while the 
ENSEMBL database for the GRC38 genomes contain information about 58051 human genes 
and 49671 for mouse. 
Count table objects were imported into the R environment and tests for differential transcript 
levels between groups were conducted using the well-established Biocounductor packages 
DESeq220 and edgeR.221 For Paper I sequential pair-wise comparisons using DESeq sufficed 
while the more complex experimental setups in Paper II and Paper IV required a more 
complex modeling approach which was implemented using the glmQLF222 workflow from 
the edgeR package. Briefly about the normalization of read counts to library sizes and to 
feature (gene) length, Paper I present expression values as transcript per million (TPM) while 
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the subsequent Paper II and IV presents the expression as reads per kilobase per million of 
reads (RPKM). While the two are related they differ slightly in regards to how the data is 
normalized. RPKM, (or the equivalent fragments per kilobase per million of reads (FPKM), 
which is often used for paired end data) is calculated based on the relationship between the 
number of counted fragments for each feature in relation to the total number of mapped 
fragments in the cDNA library and to the length of the feature in base pairs.223 TPM in 
addition takes both feature length and library size into consideration and also adjusts for the 
length of all expressed transcripts.224 
3.4.6 Gene set overrepresentation tests and GSEA 
To ascribe functional categories to sets of genes with transcript level differences between 
conditions gene set databases such as the KEGG pathway database225,226, the GO biological 
processes227,228 or the Hallmark229 gene sets from the MSigDb230 have been used in 
conjunction with methods to test for enrichment. Basic enrichment tests for significant 
overlaps between differentially expressed and/or clustered genes and gene lists from the 
databases above or gene signature lists acquired elsewhere were conducted using Fisher’s 
exact tests, adjusting for multiple testing by the false discovery rate (FDR) when multiple 
sequential tests were conducted. Gene set enrichment analysis (GSEA) produces a similar 
result but the approach is slightly more powerful as it takes expression levels from the global 
gene expression data into account and thereby gives more weight to the most significant 
genes with the highest fold change.231 All genes for which expression data has been acquired 
are ordered so that one end of the list is associated with the most interesting genes for one 
condition and the other end contain the most interesting genes for the other condition, for a 
pair-wise comparison one might use log2 transformed fold change values multiplied by the 
negative log10 transformed adjusted P-values. The GSEA can for instance be conducted either 
by submitting gene expression data to the software provided by Broad Institute or by feeding 
a pre-ranked list to the Bioconductor package fGSEA.232 This produces a list of gene sets 
presented with the level of enrichment (expressed as a normalized enrichment score NES) 
and significance level (FDR adjusted P-value). 
3.4.7 Genome-wide identification of E-box motifs 
The canonical E-box motif CACGTG, which the MYC/MAX heterodimer has the highest 
affinity for, was aligned to the mouse reference genome GRCm38.87 using the short read 
aligner Bowtie (v1.2.0)233 rendering 271113 unique alignment locations. The output bam file 
containing read alignment coordinates was converted to a bed file using BEDTools (v2.27.1) 
and distances between the aligned E-boxes to the closest transcription start site (TSS) for 
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known features in the ENSEMBL database were calculated using the script annotatePeaks.pl 
from the Homer package (http://homer.ucsd.edu/homer). To tests whether the clustered genes 
in Paper IV had E-box motifs closer to the TSS or whether they contained a higher number 
of E-box motifs within a certain distance from the TSS a Z-score was calculated based on 
1000 resampling permutations within the set of non-regulated genes. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
As stromal cells can protect malignant B cells from undergoing both spontaneous and drug 
induced apoptosis153,186 we sought to investigate the implications of microenvironmental 
signaling by stromal cells on MCL cells, both in relation to function and gene expression. 
For this purpose, a co-culture model system was developed using the murine stromal cell line 
MS-5 and the MCL cell line JeKo-1. A subset of the MCL cells, which normally grow in 
suspension, adhered strongly to the stromal cell monolayer. This has previously been 
observed in similar systems.163,234 The intercellular interaction was stable as a subsequent 
addition of fresh MCL cells in 10-fold excess, after the first set had been allowed to adhere 
to the stromal cells for 24 hours and the suspension fraction had been poured off, could not 
displace the already bound MCL cells by competing for the same binding sites and the first 
bound cells remained bound during the following 24 hours. The stable adhesion of a subset 
of the MCL cells to the stromal cell mono-layer prompted us to investigate differences in 
global gene expression between the adherent fraction and the cells remaining in suspension 
by RNA sequencing. 
Using a murine stromal cell line made possible immediate RNA isolation from the mixed 
fraction of adherent cells followed by library preparation and short read generation by 
massive parallel sequencing by means of the Illumina platform. The mixed libraries were 
subsequently deconvoluted in silico using species-based read separation. Isolated RNA from 
suspension cells in co-culture were subject to the same workflow as the mono-cultured MCL 
and stromal cells that were included as control. 1050 genes were found to have significantly 
changed transcript levels between adherent and suspension MCL cells in co-culture, 
including cytokines such as e.g. IL10, CSF1, CCL22, CCL3 and CCL4 as well as NF-kB 
pathway components like: NFKB1, NFKB2, NFKBID and NFKBIE and surface receptors 
such as e.g. TNF and CD40, anti-apoptotic BCL2L1 and the adhesion molecule ICAM1, all 
with higher expression in the adherent MCL cells. A subsequent functional classification of 
the differentially regulated genes between adherent and suspension cells in co-culture led to 
the identification of four functional themes, three for genes with higher mRNA levels in the 
adherent cells: B-cell receptor activation and immune cell signaling, apoptosis and anti-
apoptosis and cell adhesion and migration, as well as early mitosis which was associated with 
genes with lower transcript levels in the adherent cells. 
100 genes had significantly altered transcript levels between the mono- and co-cultured MS-
5 stromal cells. While there were interesting genes among the regulated, such as an increase 
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in the immunomodulatory cytokines Ccl2 and Ccl7, the experimental setup was not designed 
for detecting gene expression changes in the stromal cell fraction as only a minority of these 
cells were physically interacting with an MCL cell, which diluted the signal for gene 
expression changes resulting from a physical cell-cell interaction. 
When the 1050 differentially expressed genes between adherent and suspension MCL cells 
from the present study were interrogated for overlaps with previously published data sets that 
describe gene expression differences between lymphoma/leukemia cells residing in the 
lymph nodes and those in circulation for MCL and CLL patients, significant overlaps in 
regulated genes were found (Intersect: 348 genes (Fisher’s exact test P = 8.2x10-38) and 228 
genes (Fisher’s exact test P = 2.7x10-38), respectively). 116 of these genes were present in all 
three data sets and out of these 65 displayed a conserved direction of regulation between the 
studies and out of these we identified a core set of thirteen genes that were all changed more 
than two-fold in the present study (CCL3, CCL4, DUSP4, ETV5, ICAM1, IL15RA, IL21R, 
IL4I1, MFSD2A, NFKB1, NFKBIE, SEMA7A, TMEM2). Future studies of these thirteen 
genes investigating their roles in adhesion, intercellular communication as well as dissecting 
possible prognostic properties would be of interest. 
The observed increased levels of CCL3 and CCL4 are consistent with previous observations 
in co-cultures of MCL or CLL cells and for lymphoma cells stimulated with anti-IgM,78,235 
which may have implications for an immunomodulatory response, attracting regulatory T-
cells.236 Increased CCL3 and CCL4 serum levels have also been associated with an inferior 
prognosis in DLBCL237 and in CLL238 where they decrease rapidly upon Ibrutinib treatment 
initiation.239 Increased secretion of the chemokine CCL22 by FL cells has been shown to 
actively recruit TReg cells to the tumor tissue.178 Interestingly, and which was not granted 
space in the published manuscript, there was a strong up-regulation of IL-10 in the adhered 
MCL co-culture fraction along with the up-regulation of several genes related to BReg cells 
such as PDCD11240 (2-fold increase in the adhered MCL fraction). This led us to investigate 
the intersect between genes with significantly altered transcript levels between suspension 
and adherent MCL co-culture fractions and an experimentally determined BReg gene signature 
(27 genes) where we found a significant enrichment for genes with a stronger mRNA 
expression in the adhered MCL cell fraction (intersect: 7 genes, Fisher’s exact test P-value = 
0.0009, Figure 2).241 Among the differentially expressed genes overlapping with the BReg cell 
expression profile apart from IL-10 were the transcription factor IRF4, important during B 
cell development, HES1 implicated in notch signaling, the early growth response gene EGR3, 
the TNF superfamily member LTA, SRM which is a mediator of growth and differentiation 
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as well as the surface molecule SLAMF1. Although, most of the BReg signature genes did not 
exhibit differential gene expression between the adhesion–suspension MCL cell fractions, 
the notion of a malignant cell capable of acting immunosuppressive upon contact with 
stromal cells, a trait normally reserved for infiltrating regulatory T and B cells, is intriguing. 
Interestingly, it has been reported that CLL cells themselves can adopt regulatory 
characteristics in response to appropriate external stimuli.151 The over-lapping genes 
identified here might represent a module of genes that can elicit a subset of BReg behavior. 
 
Figure 2. Relative transcript levels for 27 regulatory B-cell signature genes. ADH (adherent MCL cells in co-
culture), SEP (mono cultured MCL cells), SUSP (suspension MCL cells in co-culture). 
 
We concluded that, while there are differences between the results from the present in vitro 
study and those based on patient material, the co-culture model system reproduces a 
significant part of the gene regulation observed in vivo and that this model system, or future 
incarnations thereof, can be utilized for studying aspects of the microenvironmental 
interactions also observed in MCL and CLL patients. 
4.2 PAPER II 
Building and expanding on the results from Paper I a second co-culture model system was 
developed, using MS-5 stromal cells and the MCL cell line REC-1. Similar to JeKo-1, REC-
1 adhered strongly to the stromal cell monolayer but significantly fewer cells attached and in 
contrast to JeKo-1, where an increase in cumulative adhesion over time could be observed, 
the number of adhered cells did not significantly increase following 4 hours of co-culture. 
Additionally, REC-1 cells migrated to a lower extent towards conditioned media from 
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stromal cells than JeKo-1 cells. Global gene expression data similar to that in Paper 1 was 
generated for the REC-1 co-culture conditions and for consistency the JeKo-1 data was 
reanalyzed in parallel using an updated workflow including: the most recent reference 
genome versions, quicker and more accurate alignment using the short-read aligner STAR 
combined with an analysis workflow based on generalized linear models by the edgeR 
Bioconductor package, which allow for more complex experimental designs. Given that 
every step of the analysis workflow was exchanged the net result for the reanalyzed JeKo-1 
data set was relatively consistent (Figure 3). 
 
Figure 3 Comparison of gene expression changes (log2 fold change, genes with significantly altered transcript 
levels) between adherent and suspension JeKo-1 cells using the workflow presented in Paper I (deseq1, on x-
axis) compared to the updated workflow implemented in Paper II (edgeR, y-axis). 
 
Significant differences in transcript levels between adherent and suspension cells in co-
culture were observed for 549 and 291 genes for JeKo-1 and REC- cells respectively (FDR 
q-value < 0.05, absolute fold change > 1.5). Surprisingly, merely 34 genes were significantly 
changed at the transcript level in both cell lines in response to adhesion to the stromal cell 
mono-layer. Several of the concordantly down-regulated genes were of mitochondrial origin 
with functions in the respiratory chain. The small overlap prompted an analysis of the 
differences in response to adhesion between JeKo-1 and REC-1 which rendered a list of 590 
genes that were significantly differentially regulated between JeKo-1 and REC-1 as the cells 
adhered to the stromal cell mono-layer. Among these genes were several that had been 
identified belonging to a core signature of thirteen genes in Paper I such as CCL3, CCL4, 
ICAM1, NFKB1 and NFKBIE that were also differentially regulated in MCL and CLL patient 
samples. A subsequent GSEA using a ranked list of genes based on differences in response 
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enrichment of nine gene sets from the KEGG pathway database, including B-cell receptor 
signaling and Apoptosis. Consistently, there was a significant overlap of genes with 
differential responses to adhesion between JeKo-1 and REC-1 and published signatures for 
BCR and NF-kB signaling. However, stimulating the cells with anti-IgM antibodies led to 
the phosphorylation of BTK and PLCg in both cell lines and increased levels of the cytokines 
CCL3 and CCL4—which are known to be upregulated upon BCR stimulation235—in the 
conditioned media. Both JeKo-1 and REC-1 thus appeared to express a functional BCR but 
upon adhesion there was a significant difference in BCR signaling engagement between the 
two cell lines. Similarly, knocking down BTK, which functions downstream of the BCR, or 
inhibiting its function by the covalently bound small-molecule Ibrutinib led to a reduction in 
stromal cell-bound JeKo-1 cells but had no measurable effect on the number of adhered REC-
1 cells. 
The surface receptor CXCR4 was among the genes with significant differences in differential 
regulation upon adhesion. CXCR4 mRNA and cell surface levels were decreased in JeKo-1 
and REC-1 cells upon adhesion and the negative regulation was significantly higher in JeKo-
1. The reduced CXCR4 levels in the adherent fraction is consistent with previous studies 
where lower CXCR4 surface levels have been found for cells of lymph node origin when 
compared to cells in circulation.67,72 Attenuation of CXCR4 signaling by addition of the 
agonist plerixafor (a small molecule also known as AMD3100) significantly decreased 
migration towards CXCL12 and reduced adhesion to the stromal cell mono-layer for JeKo-
1cells, while no significant effect was observed for REC-1. 
Reduced cell surface levels of ICAM1 by siRNA knock-down led to a reduction in the 
number of adhered MCL cells while knocking down sphingosine-1-phosphate receptor 1 
(S1PR1) increased the number of adhered JeKo-1 and REC-1 cells. S1PR1 has been 
suggested to have diagnostic properties in MCL,242 and missense mutations affecting S1PR1 
have been shown to be more frequent among relapsing MCL patients.243 Consistent with the 
present study, increased S1PR1 levels upon BTK inhibition by Ibrutinib244 as well as a 
reduction in S1PR1 levels upon anti-IgM or CXCL12 stimulation or in co-cultures with nurse 
like cells245 has been shown in CLL. 
The importance of the BCR for lymphoma development and progression has been described 
previously as has the possibility of targeting BCR signaling for treatment of B-cell 
lymphomas, reviewed by R. Young and L. Staudt.246 BCR signaling important for the survival 
of MCL cells can be conferred by the TME 66,68,247 To target intrinsic aberrant BCR signaling 
or TME-mediated BCR signaling, small molecules targeting the BCR-axis by inhibition of 
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e.g. the spleen tyrosine kinase (SYK),191,248 Phosphatidylinositol 3-kinase d (PI3Kd)249,250 or 
BTK251 have been developed for treatment of MCL and CLL patients. The irreversibly-
binding BTK inhibitor Ibrutinib, has proven successful for treatment of MCL77,252 and 
CLL76,253 and has been shown to promote a rapid migration of MCL cells into circulation 
following treatment initiation.78 Resistance to Ibrutinib has however been reported,254 with 
plausible mechanistic explanations being missense-mutations affecting cysteine 451 in the 
region where Ibrutinib binds to BTK, leading to a reversible binding, or through mutations 
to PLCg, leading to constitutive downstream BCR signaling.255 Another suggested, possible 
culprit for Ibrutinib resistance in MCL could be supportive signaling mechanisms provided 
by the TME.256 A second generation BTK inhibitor, Acalabrutinib, allegedly with improved 
specificity for BTK, has recently been approved for the treatment of refractory MCL.81 
Blocking BCR signaling through BTK inhibition by Ibrutinib has been shown to reduce 
serum levels of the cytokines CCL3 and CCL4 in MCL and CLL,78,239 which is consistent 
with in vitro observations where the levels of CCL3 and CCL4 increase in the conditioned 
media of MCL and CLL cells upon co-culture or when stimulated with anti-IgM.235 High 
serum levels of CCL3 and CCL4 have additionally been associated with a poor prognosis in 
CLL and DLBCL.237,238 The present study shows that different MCL cells have different 
dependencies on BCR signaling in relation to their interaction with their immediate 
microenvironment, which could lead to a differential response to treatments where aspects of 
BCR signaling are being targeted. 
In conclusion, the two MCL cell lines JeKo-1 and REC-1 have different dependencies for 
adhesion to and intercellular communication with stromal cells. BCR signaling was 
important for the adhesion of JeKo-1 to stromal cells but not for REC-1. Similarly, the 
chemokine receptor CXCR4 was implicated in adhesion and migration of JeKo-1 cells but 
not for REC-1. Lowered surface levels of the adhesion molecule ICAM1 reduced the 
adhesion of both cells to stromal cells while reducing the levels of S1PR1 led to an increase 
in the number of attached cells. This prompts for future studies validating the findings from 
the present study and subsequently investigating the possibility of targeting proteins for 
which a common dependency was observed in relation to adhesion. The in vitro model 
system described in the present study may thus be used to identify pathways and mechanisms 
that in turn can be used to identify patients that will respond to different forms of treatment. 
4.3 PAPER III 
The study made use of an inducible system to investigate the impact of SOX11 over-
expression in the Ba/F3 pro-B cell line. Constitutive over-expression of SOX11 for 72 hours 
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led to a gradual aggregation of cells. Following 72 hours of SOX11 over-expression the 
Ba/F3 cells formed large aggregates, had lower metabolic activity as measured by XTT and 
a lower 3H Thymidine incorporation rate. A global gene expression analysis by microarray 
identified 534 significantly changed genes with higher and 338 with lower transcript levels 
in the SOX11 over-expressing (SOX11-on) cells as compared to control, including higher 
transcript levels for Mmp8 and S110A8/9 as well as the protocatherin-b genes Pcdhb16 and 
Pcdhb17. In addition, the cells appeared to retain their B-cell identity as the pro-B-cell 
restricted genes Id1 and Tal were increased at the transcript level while no significant change 
was detected for other genes typically associated with specific B-cell developmental 
stages.257 A gene set enrichment analysis of the global gene expression data identified several 
cell cycle related gene sets that were enriched for among the genes with increased transcript 
levels in the SOX11-on cells, and importantly they contained several checkpoint genes like 
Chek1 and Chek2 as well as DNA damage response genes like Trp53, Brca1 and Brca2. The 
net result was reduced proliferation. Among the enriched gene sets for genes with lower 
transcript levels were those associated with leukocyte function and immunomodulatory 
pathways. We concluded that in the context of the Ba/F3 cell system, SOX11 did not act as 
an oncogene. Interestingly, the oncogenic properties of SOX11 in MCL have been debated 
and the results have been divergent and collectively inconclusive.50,52,54,55 If anything, the 
importance of the cellular context for the net response upon SOX11 induction/depletion has 
been underlined. It is therefore interesting to note that in this particular cellular system 
SOX11 did not elicit explicit oncogenic activity which of course does not exclude the 
possibility of other outcomes at other B-cell differentiation stages, in other cellular 
backgrounds, or in other microenvironmental contexts. 
4.4 PAPER IV 
A model system was developed for doxycycline-regulated control of wild type MYC levels 
or for MYC carrying either of the lymphoma-associated missense mutations T58A or T58I 
in murine splenic B-cells. The transformed cells were generated through simultaneous 
lentiviral transduction of BCL2L1 and BMI1, to inhibit apoptosis and DNA damage 
response, alongside a vector carrying Tet-on constructs allowing for progressive regulation 
of MYC levels. MYC protein levels, when measured by western blot, indicated consistently 
higher levels for T58A for any doxycycline dose when compared to WT or T58I, possibly 
due to increased protein stability as has previously been reported.118 As the level of MYC 
increased so did cellular proliferation rate. A gradual increase in MYC levels also led a lower 
portion of cells in G0/G1 and a higher portion in the S phase of the cell cycle as the cells 
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stained with propidium were assessed by flow cytometry. Interestingly, consistently for all 
functional readouts, the response is more sensitive and subsequently of higher magnitude for 
T58A as compared to WT which has a more sensitive and higher response when compared 
to T58I, consistent with the order of previous observations in regards of transforming 
capacity.119 The phenotypic differences together with previous observations of differences in 
gene regulation between WT and T58I118 led us to investigate differences in gene regulation 
between the three B-cell types expressing different MYC genotypes by next generation 
sequencing. 
mRNA was extracted for cells expressing seven different levels of MYC for WT, T58A and 
T58I and cDNA libraries were prepared and sequenced using the Illumina platform 
generating on average 29 million 50 bp single-end reads per sample. Reads were subject to 
quality control and trimmed based on sequence quality, and subsequently aligned to the latest 
mouse reference genome GRCh38.87 concatenated with the sequences for MYC, BCL2L1, 
BMI1 and EGFP, which were all over-expressed in the transduced cells. Aligned reads per 
gene (concatenated exons) were assessed by the featurecounts function of the SubRead 
package and, using the glmQLF workflow of the edgeR package, following threshold-based 
removal of genes with consistently low read counts, the per gene expression was modeled 
using generalized linear models that were then used to test for significant gene profiles. While 
the three MYC genotypes were different in terms of global gene expression level their 
response to progressively increasing MYC levels were consistent, as shown by the principal 
component analysis. 
7263 genes were significantly altered at the transcript level as the levels of WT MYC 
increased, in addition 347 genes were regulated significantly differently in response to 
increasing MYC levels between WT and T58A while 683 were differentially regulated 
between WT and T58I. The union of lists with differentially regulated genes was thereafter 
subject to division into 12 clusters by agglomerative hierarchical clustering based on log2 
transformed RPKM values. For two clusters a significant enrichment of non-coding genes 
was found. Consistent with previous observations about MYC and E-box motifs, most 
clusters containing a majority of genes with increasing transcript levels following an increase 
in MYC levels contained more genes with E-boxes within 1000 bp of the TSS.  
The genes in each cluster were subsequently functionally classified through hypergeometric 
tests for overrepresentation in gene sets from the gene ontology database for biological 
processes and in gene sets from the KEGG pathway database. Some clusters contained genes 
related to processes that have previously been described to change in response to increased 
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MYC levels (e.g. de novo pyrimidine and purine synthesis258, cell cycle progression as well 
as ribosome biogenesis259). Other clusters contained genes in gene sets which have not been 
described in relation to increased MYC levels before (e.g. functions related to B-cell identity 
and Chemotaxis, which were enriched for in clusters containing genes that were down-
regulated as the level of MYC increased). 
When interrogating the overlap between genes that were differentially expressed upon an 
increase in WT MYC levels in the present study and genes that were found to be differentially 
expressed in the Eµ-Myc mouse model between cells at three different stages of 
lymphomagenesis, with progressively increasing MYC levels, a significant intersect of 
commonly regulated genes was found (intersect 3991 genes, Fisher’s exact test P-value = 
1.7x10-8).127 All previously defined clusters were represented in the intersect but notably we 
observed a significant enrichment of genes in the three clusters that contained genes involved 
in ribosome biogenesis, purine metabolism and pyrimidine metabolism. Interestingly, a 
significant overlap was also found between genes significantly changed upon progressively 
increasing WT MYC levels and a gene signature containing 100 direct MYC targets (intersect 
71 genes, Fisher’s exact test P-value = 1.6x10-28) and more importantly the genes in the 
intersect were significantly enriched for among the most significant genes in the present 
study.140 These two observations strengthened the notion of a model system that represent 
aspects of gene expression regulation by MYC independently observed elsewhere. 
Consistent with previous studies, MYC carrying lymphoma-associated mutations at 
threonine 58 regulate the expression of genes differently from WT,118 and interestingly, while 
T58A and T58I commonly can regulate a set of genes differently from WT they do also 
regulate the expression of genes differently between the two. The mutant phenotype is not 
merely due to the inability to phosphorylate threonine 58 but seems also to reflect different 
conformational properties of the proteins containing the T58A and T58I substitutions. We 
concluded that the model system can be used to further study functional changes in response 
to different MYC levels and that it can also be used for a more elaborate characterization of 
how the lymphoma-associated MYC mutants affect cancer progression in B-cells. 
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5 CONCLUDING REMARKS 
It is interesting to note the importance of the cellular background and the context in which 
the cell resides when assessing gene expression changes inflicted by external or internal 
events. With this in mind, the key for finding ways to manage MCL and other malignancies 
that are difficult to cure possibly does not lie in their genetic makeup and probably not in the 
microenvironmental context either but in a combination of the two. Developing and 
characterizing model systems such as the ones presented here may prove useful for designing 
and testing treatment approaches for targeting microenvironmental interactions that are 
specific to lymphoma subsets. The controlled nature of the in vitro models is of course 
compelling but their lack of complexity may cause issues as they may exclude important 
components, illustrated by the discrepancy between the efficacy of certain compounds in 2D 
monocultures as compared to their in vivo effect. Regardless of the level of refinement the 
relevance of these systems will have to be evaluated in relation to in vivo situations and for 
that the evolving single cell omics techniques, such as for instance: spatial transcriptomics, 
single cell ATAC-seq and single cell bisulfite sequencing will likely prove important. 
Microenvironment-related findings from the present thesis such as the importance of surface 
molecules like for instance ICAM1, CXCR4, S1PR1 and the BCR will have to be evaluated 
in other in vitro and in vivo systems to investigate their universality in propagating survival 
or adhesion related mechanisms to the malignant cell. Including different model systems can 
have a confirmatory role but also a role in finding different genes that potentially could be 
used for disease stratification or for to be targeted in different patient subgroups. Future 
experiments could for instance involve different in vitro cell systems, possibly through the 
use of 3D cultures and inclusion of more than one supportive cell type. Similar systems could 
be developed for ex vivo propagation of lymphoma cells. 
Interestingly, given the documented role of MYC in cell trafficking and homing, as illustrated 
by its role in the GC reaction, it would be of interest to subject the B-cells presented here, 
with regulable MYC levels, to the adhesion assay presented in Paper I and II. Given the 
omnipresent and pluralistic role of MYC in human malignancies it would be unsurprising if 
it also had a role in survival-promoting microenvironmental interactions.  
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